{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:05:28Z","timestamp":1768781128588,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.atherosclerosis.2015.05.032","type":"journal-article","created":{"date-parts":[[2015,6,5]],"date-time":"2015-06-05T15:43:04Z","timestamp":1433518984000},"page":"322-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The impact of LDLR function on fibroblast growth factor 21 levels"],"prefix":"10.1016","volume":"241","author":[{"given":"Joost","family":"Besseling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7229-7614","authenticated-orcid":false,"given":"Kwok Leung","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roeland","family":"Huijgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry-Anne","family":"Rye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.Kees","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Hutten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/cen.12095","article-title":"Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives","volume":"78","author":"Woo","year":"2013","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell. Metab."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11684-013-0244-8","article-title":"Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology","volume":"7","author":"Li","year":"2013","journal-title":"Front. Med."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib4","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib5","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1210\/en.2009-0221","article-title":"Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity","volume":"150","author":"Berglund","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21","volume":"5","author":"Inagaki","year":"2007","journal-title":"Cell. Metab."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib7","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","article-title":"Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states","volume":"5","author":"Badman","year":"2007","journal-title":"Cell. Metab."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib8","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cell.2011.11.062","article-title":"Fibroblast growth factor-21 regulates PPAR\u03b3 activity and the antidiabetic actions of thiazolidinediones","volume":"148","author":"Dutchak","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1089\/dna.2013.2290","article-title":"FGF21 increases cholesterol efflux by upregulating ABCA1 through the ERK1\/2-PPAR\u03b3-LXR\u03b1 pathway in THP1 macrophage-derived foam cells","volume":"33","author":"Lin","year":"2014","journal-title":"DNA Cell. Biol."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib11","doi-asserted-by":"crossref","first-page":"12602","DOI":"10.1074\/jbc.M112.341248","article-title":"Fibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip\/Idol and the Canopy2 (Cnpy2)\/Mylip-interacting saposin-like protein (Msap)","volume":"287","author":"Do","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib12","series-title":"Metab. Mol. Bases Inherit. Dis","first-page":"2863","article-title":"Familial hypercholesterolaemia","author":"Goldstein","year":"2001"},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib13","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/eurheartj\/eht015","article-title":"Diagnosis and treatment of familial hypercholesterolaemia","volume":"34","author":"Hovingh","year":"2013","journal-title":"EHJ"},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/CIRCGENETICS.110.959239","article-title":"Assessment of carotid atherosclerosis in normocholesterolemic individuals with proven mutations in the low-density lipoprotein receptor or apolipoprotein B genes","volume":"4","author":"Huijgen","year":"2011","journal-title":"Circ. Cardiovasc Genet."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(00)03587-X","article-title":"Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands","volume":"357","author":"Umans-Eckenhausen","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib16","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/humu.21258","article-title":"Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia","volume":"31","author":"Huijgen","year":"2010","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib17","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1093\/eurheartj\/ehs038","article-title":"Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants","volume":"33","author":"Huijgen","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.atherosclerosis.2007.12.024","article-title":"Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors","volume":"200","author":"Alonso","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib19","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1161\/01.ATV.20.9.e41","article-title":"Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype","volume":"20","author":"Bertolini","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib20","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1210\/jc.2012-2267","article-title":"Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes","volume":"97","author":"Ong","year":"2012","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00125-014-3458-7","article-title":"The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the fenofibrate intervention and event lowering in diabetes study","volume":"58","author":"Ong","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib22","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2337\/dc11-0294","article-title":"High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects","volume":"34","author":"Chen","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib23","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1373\/clinchem.2010.155184","article-title":"Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans","volume":"57","author":"Yu","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib24","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1034\/j.1399-0004.2000.570205.x","article-title":"Molecular genetic testing for familial hypercholesterolemia: spectrum of LDL receptor gene mutations in The Netherlands","volume":"57","author":"Lombardi","year":"2000","journal-title":"Clin. Genet."},{"key":"10.1016\/j.atherosclerosis.2015.05.032_bib26","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1210\/jc.2012-1221","article-title":"Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis","volume":"97","author":"Reinehr","year":"2012","journal-title":"J.\u00a0Clin. Endocrinol. Metab."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015013465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015013465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T02:49:48Z","timestamp":1599101388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915015013465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0021915015013465"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.05.032","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of LDLR function on fibroblast growth factor 21 levels","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.05.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}